Target
NMT2
2 abstracts
Abstract
Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.Org: BC Cancer Centre for Lymphoid Cancer, Pacylex Pharmaceuticals, Inc.,
Abstract
A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.Org: Cross Cancer Institute, Centre Hospitalier de l’Université de Montréal/CRCHUM, Princess Margaret - University Health Network, BC Cancer Centre for Lymphoid Cancer, Pacylex Pharmaceuticals, Inc.,